Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inviragen, a developer of vaccines against infectious diseases, is set to commence a placebo controlled randomized Phase 1 clinical trial of its experimental vaccine INV21 for Hand, Foot and Mouth Disease (HFMD) in Singapore.
Subscribe to our email newsletter
INV21 is a highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71 (EV71).
The study will evaluate the safety of INV21 along with immune responses in healthy adult volunteers aged 21 to 45 years.
Each adult volunteer will receive two immunizations separated by four weeks and will be monitored for any adverse reactions after each administration.
Immune responses to INV21 will be measured one, two and six months after the second immunization.
Inviragen’s chief operating officer Joseph Santangelo said this first clinical study of INV21 is the result of years of research by Inviragen’s scientists, and is an important milestone for the company.
"INV21 was developed in Singapore by Inviragen and our preclinical studies have demonstrated that this vaccine induces broad, neutralizing antibodies to multiple EV71 isolates," Santangelo said.